

# Intra-Abdominal Fat and Elevated Urine Albumin Excretion in Men With Type 1 Diabetes

SHALAMAR D. SIBLEY, MD, MPH<sup>1</sup>  
IAN H. DE BOER, MD, MS<sup>2</sup>  
MICHAEL W. STEFFES, MD, PHD<sup>1</sup>  
JOHN D. BRUNZELL, MD<sup>2</sup>

THE DIABETES CONTROL AND  
COMPLICATIONS TRIAL/EPIDEMIOLOGY OF  
DIABETES INTERVENTIONS AND  
COMPLICATIONS (DCCT/EDIC)  
RESEARCH STUDY GROUP

Earlier studies documented associations between central obesity and elevated albumin excretion rate or other renal injury indicators in nondiabetic subjects (1–11). A retrospective study conducted in a Kaiser Permanente mixed diabetic-nondiabetic cohort suggested that obesity increased risk for progression to end-stage renal disease (12). Studies also identified obesity as a risk factor for renal disease in type 1 diabetes (13,14). We previously examined obesity-related factors and albumin excretion within the total Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Conducted between 1982 and 1993, the DCCT included 1,441 subjects with type 1 diabetes randomized to intensive or conventional diabetes treatment and followed for 6.5 years on average. Details of resources utilized for the DCCT/EDIC (observational follow-up) study designs were previously published (15–18). These studies demonstrate the powerful effect of intensive insulin therapy on preventing and slowing progression of micro- and macrovascular complications and established intensive therapy as the current standard of diabetes care for patients with type 1 diabetes. However, type 1 diabetic subjects, like the general population, are becoming heavier and more at

risk for obesity-related complications (19). In our cross-sectional analysis 4 years after the end of the DCCT, waist-to-hip ratio (WHR), a visceral fat surrogate, was associated with elevated albumin excretion (20). In our longitudinal analysis, waist circumference was associated with subsequent development of persistent microalbuminuria (21). For this current analysis, we hypothesized that intra-abdominal fat (IAF) in particular relates more strongly to elevated albumin excretion than abdominal subcutaneous fat (SQF).

## RESEARCH DESIGN AND METHODS

We analyzed IAF and other obesity measures in relation to urine albumin excretion in a group of men with type 1 diabetes. This study included DCCT/EDIC study participants ( $n = 64$  men) at four participating DCCT/EDIC sites. Subjects were studied at the University of Washington ( $n = 32$ ) between November 1997 and November 1999 and at the University of Minnesota ( $n = 32$ ) between November 2001 and November 2003. Subjects studied at the University of Minnesota were recruited from three Minnesota DCCT/EDIC sites: the University of Minnesota ( $n = 20$ ), International Diabetes Center ( $n = 11$ ), and Mayo Clinic ( $n = 1$ ). This analysis was restricted to men because only one woman had an

elevated albumin-to-creatinine ratio (ACR). Written informed consent was obtained; the study was approved by the respective institutional review boards.

Single-slice umbilical abdominal computed tomography scans for IAF and SQF were read by one trained technician at each center, each blinded to the case/control status of study participants, utilizing well-validated software and analysis techniques (22–24). Urine was collected from second-morning voids (the mean of two different-day samples when possible). Participants with symptoms and urinary findings consistent with urinary tract infection were excluded. Urinary creatinine and microalbumin were measured at the Core DCCT/EDIC Laboratory, University of Minnesota (15). Elevated urine ACR was defined as  $\geq 30$  mg/g creatinine. A1C, history, and anthropometric measurements were assessed annually at DCCT/EDIC visits with standardized forms (25,26). Measures of obesity were compared using a two-sample  $t$  test, assuming unequal variance. Logistic regression was used to estimate the associations of obesity measurements with ACR status, with and without adjustment for potential confounders. STATA software (version 8.1; Stata, College Station, TX) was utilized for statistical analyses (27).

**RESULTS**— Of 64 men, 9 had elevated urine ACR  $\geq 30$  mg/g (6 had microalbuminuria [ACR 30–300 mg/g], and 3 had clinical albuminuria). Compared with men with normal ACR, men with ACR  $\geq 30$  mg/g were more likely to have received conventional insulin therapy during the DCCT, smoke, use ACE inhibitors, and have greater blood pressures, greater A1C, and dyslipidemia (higher LDL cholesterol [ $P = 0.001$ ] and triglyceride [ $P = 0.002$ ]).

IAF was greater in men with elevated ACR compared with men with normal ACR ( $P = 0.048$ ); SQF was not (Table 1). Waist circumference ( $P = 0.048$ ) and WHR ( $P = 0.006$ ) were greater in men with elevated ACR, and BMI showed a similar trend ( $P = 0.077$ ).

In logistic regression, elevated ACR was associated ( $P < 0.05$ ) with greater

From the <sup>1</sup>Department of Endocrinology and Diabetes, University of Minnesota, Minneapolis, Minnesota; and the <sup>2</sup>School of Medicine, University of Washington, Seattle, Washington.

Address correspondence and reprint requests to Shalamar D. Sibley, Endocrinology and Diabetes, University of Minnesota, Mayo Medical Code 101, 420 Delaware St. SE, Minneapolis, MN 55455. E-mail: sible004@umn.edu.

Received for publication 15 November 2006 and accepted in revised form 11 April 2007.

Published ahead of print at <http://care.diabetesjournals.org> on 24 April 2007. DOI: 10.2337/dc06-2345.

**Abbreviations:** ACR, albumin-to-creatinine ratio; IAF, intra-abdominal fat; SQF, abdominal subcutaneous fat; WHR, waist-to-hip ratio.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2007 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Table 1—Comparison (t test) and regression analyses of obesity measures in relation to urine ACR

Obesity measure	Comparisons				Regressions						
	ACR <30		ACR ≥30		Scale*	Unadjusted			Adjusted†		
	ACR <30	ACR ≥30	p	p		β	r <sup>2</sup>	P	β	r <sup>2</sup>	P
IAF	82 ± 44	136 ± 69	0.048		52 cm <sup>2</sup>	0.99	0.151	0.012	0.95	0.262	0.020
SQF	212 ± 100	277 ± 134	0.199		106 cm <sup>2</sup>	0.62	0.055	0.100	0.66	0.197	0.096
BMI	26.6 ± 2.8	29.5 ± 4.3	0.077		3.2 kg/m <sup>2</sup>	0.92	0.126	0.017	1.28	0.330	0.006
Waist circumference	93 ± 8	102 ± 11	0.048		9.0 cm	1.05	0.138	0.016	1.18	0.286	0.014
WHR	0.90 ± 0.06	0.95 ± 0.04	0.006		0.06	0.99	0.118	0.013	0.88	0.209	0.072

Data are means ± SD unless otherwise indicated. \*Each independent variable scaled to its SD to facilitate comparisons. †Each logistic regression model adjusted for age, smoking status, and A1C.

levels of each obesity measure, except SQF (Table 1). When IAF and SQF were included as dependent variables simultaneously, magnitude of association for IAF did not change ( $\beta = 0.98$  vs.  $\beta = 0.99$ ) and retained statistical significance ( $P = 0.035$ ), and SQF was not associated with elevated ACR ( $\beta = 0.02$ ,  $P = 0.965$ ). After adjustment for age, A1C, and smoking status, magnitudes of association with elevated ACR were similar for IAF, BMI, waist circumference, and WHR, with the association for BMI strongest ( $\beta = 1.28$ ). Diabetes duration and DCCT treatment group status were not related to obesity measures or ACR status and did not lead to meaningful changes in the associations of obesity measures with ACR status in the full models (data not shown).

**CONCLUSIONS**— In this study, we find urine ACR more strongly associated with IAF than with SQF in middle-aged males with type 1 diabetes, suggesting that metabolic factors associated with visceral rather than subcutaneous adiposity may contribute to renal injury in this population.

There are some limitations to this cross-sectional study, conducted in a small group of people. On its own, it cannot demonstrate causality. However, our prior study in this population suggested causality by demonstrating temporality between obesity and abnormal albumin excretion. Only men were analyzed; we cannot necessarily generalize these findings to women. However, our prior studies (20,21) in this population suggest that the association between central obesity and elevated albumin excretion is at least as strong in women as in men. Given sex-related anthropometric measurement differences, however, specific strengths of associations between particular obesity measures and ACR may differ somewhat in women.

In summary, this study utilizes accurate assessments of adipose distribution in a small group of individuals, more firmly substantiating the conclusion from our earlier larger cross-sectional and longitudinal epidemiologic studies (20,21) that IAF is a more important contributor to renal injury than SQF in men with type 1 diabetes. Additionally, we find that the easiest measurements to obtain in clinical settings, BMI and waist circumference, are each strong predictors of elevated ACR in these subjects. Future studies are needed to elucidate mechanisms underlying the IAF–albumin excretion link.

**Acknowledgments**— This study was supported by the National Institutes of Health (NIH) Program Project DPPG DK-02456, NIH Clinical Research Training in Renal Diseases Fellowship (to S.D.S.), Minnesota Medical Foundation Faculty Research Grant 3055-9205 (S.D.S.), the NIH K23 Mentored Patient-Oriented Career Development Award (DK-59445 to S.D.S.), NIH Grant DK007247 (to I.D.B.), NIH K30 Grant RR-022293 (to I.D.B.), the University of Washington General Clinical Research Center (GCRC) (MO1-RR00037), and the University of Minnesota GCRC (MO1-RR00400).

#### References

- Lokkegaard N, Haupter I, Kristensen TB: Microalbuminuria in obesity. *Scand J Urol Nephrol* 26:275–278, 1992
- Metcalf PA, Scragg RK, Dryson E: Associations between body morphology and microalbuminuria in healthy middle-aged European, Maori, and Pacific Island New Zealanders. *Int J Obes Relat Metab Disord* 21:203–210, 1997
- Reid M, Bennett F, Wilks R, Forrester T: Microalbuminuria, renal function, and waist:hip ratio in black hypertensive Jamaicans. *J Hum Hypertens* 12:221–227, 1998
- Solerte SB, Fioravanti M, Pezza N, Locatelli M, Schifino N, Cerutti N, Severgini S, Rondanelli M, Ferrari E: Hyperviscosity and microalbuminuria in central obesity: relevance to cardiovascular risk. *Int J Obes Relat Metab Disord* 21:417–423, 1997
- Valensi P, Assayag M, Busby M, Paries L, Lormeau B, Attali JR: Microalbuminuria in obese patients with or without hypertension. *Int J Obes Relat Metab Disord* 20:574–579, 1996
- Cirillo M, Senigalliesi L, Laurenzi M, Alfieri R, Stamler J, Stamler R, Panarelli W, De Santo NG: Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: the Gubbio Population Study. *Arch Intern Med* 158:1933–1939, 1998
- Dingel DR, Goldberg A-P, Mayuga RS, Kairis GM, Weir MR: Insulin resistance, elevated glomerular filtration fraction, and renal injury. *Hypertension* 28:127–132, 1996
- Ribstein J, du Cailar G, Mimran A: Combined renal effects of overweight and hypertension. *Hypertension* 26:610–615, 1995
- Licata G, Scaglione R, Ganguzza A, Corrao S, Donatelli M, Parrinello G, Dichiaro MA, Merlino G, Cecala MG: Central obesity and hypertension: relationship between fasting serum insulin, plasma renin activity, and diastolic blood pressure in young obese subjects. *Am J Hypertens* 7:314–320, 1994
- Scaglione R, Ganguzza A, Corrao S, Parrinello G, Merlino G, Dichiaro MA, Arnone S, D'Aubert MD: Central obesity and hypertension: pathophysiologic role of renal hemodynamics and function. *Int J Obes Relat Metab Disord* 19:403–409, 1995
- Solerte SB, Rondanelli M, Giaccherio R, Stabile M, Lovati E, Cravello L, Pontiggia B, Vignati G, Ferrari E, Fioravanti M: Serum glucagon concentration and hyperinsulinemia influence renal hemodynamics and urinary protein loss in normotensive patients with central obesity. *Int J Obes Relat Metab Disord* 23:997–1003, 1999
- Hsu CY, McCulloch CE, Iribarren C, Dar-

- binian J, Go AS: Body mass index and risk for end-stage renal disease. *Ann Intern Med* 144:21–28, 2006
13. Giorgino F, Laviola L, Cavallo Perin P, Solnica B, Fuller J, Chaturvedi N: Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetes patients: the EURODIAB Prospective Complications Study. *Diabetologia* 47:1020–1028, 2004
  14. Stuhldreher WL, Becker DJ, Drash AL, Ellis D, Kuller LH, Wolfson SK, Orchard TJ: The association of waist/hip ratio with diabetes complications in an adult IDDM population. *J Clin Epidemiol* 47:447–456, 1994
  15. DCCT Research Group: The Diabetes Control and Complications Trial (DCCT): design and methodologic considerations for the feasibility phase. *Diabetes* 35:530–545, 1986
  16. Department of Health and Human Services: The prevalence study. In *The Lipid Research Clinics Population Studies Data Book*. Vol. 1. Washington, DC, U.S. Govt. Printing Office, 1980, p. 1–115 (NIH publ. no. 80-1527)
  17. Metropolitan Life Insurance Company: Metropolitan height and weight tables. *Stat Bull Metropolitan Life Insurance Co* 64:2–9, 1983
  18. DCCT Research Group: Epidemiology of Diabetes Interventions and Complications: design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. *Diabetes Care* 22:99–111, 1999
  19. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT: Diabetes Control and Complications Trial. *JAMA* 280:140–146, 1998 [erratum in *JAMA* 280:1484, 1998]
  20. Sibley SD, Thomas W, de Boer I, Brunzell JD, Steffes MW: Gender and elevated albumin excretion in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort: role of central obesity. *Am J Kidney Dis* 47:223–232, 2006
  21. de Boer IH, Sibley SD, Kestenbaum B, Sampson JN, Young B, Cleary PA, Steffes MW, Weiss NS, Brunzell JD, the DCCT/EDIC Research Group: Central obesity, incident microalbuminuria, and change in creatinine clearance in the Epidemiology of Diabetes Interventions and Complications Study. *J Am Soc Nephrol* 18:235–243, 2007
  22. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD: The visceral adiposity syndrome in Japanese-American men. *Obesity Research* 2:364–371, 1994
  23. Shuman WP, Morris LL, Leonetti DL, Wahl PW, Moceril VM, Moss AA, Fujimoto WY: Abnormal body fat distribution detected by computed tomography in diabetic men. *Invest Radiol* 21:483–487, 1986
  24. Potretzke AM, Schmitz KH, Jensen MD: Preventing overestimation of pixels in computed tomography assessment of visceral fat. *Obes Res* 12:1698–1701, 2004
  25. Molitch ME, Steffes M, Cleary PA, Nathan DM: Baseline analysis of renal function in the Diabetes Control and Complications Trial. *Kidney Int* 43:668–674, 1993
  26. DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. *Kidney Int* 47:1703–1720, 1995